CDXS

Codexis is a pre-profitability directed-evolution enzyme company mid-pivot toward its ECO Synthesis platform for large-scale RNAi (siRNA) therapeutics manufacturing. The financials show a genuine improvement inflection: FY2025 revenue rose 18.6% to $70.4M after two years of decline (from a $139M peak in 2022 down to $59.3M in 2024), and the net loss narrowed for a third straight year to -$44.0M from -$65.3M and -$76.2M. Cash tripled to $50.8M and operating cash burn improved 60.8% to -$19.4M, giving roughly two-plus years of runway before more capital is needed. That is the bull case: a stabilizing top line, shrinking losses, and a funded balance sheet (current assets $96.8M vs. current liabilities $25.3M; cash exceeds the $40.1M of long-term debt).

But the quality bar is not met. Operating margin is -59.3%, net margin -62.5%, ROE -87%, and R&D ($52.3M) alone exceeds total revenue — this business does not yet cover its own science. The 10-K is explicit: net losses since inception, a $606.8M accumulated deficit, and no assurance of ever reaching profitability. Equity fell 24.5% to $50.5M while liabilities/equity climbed to 1.92x, and the $50.8M cash swing was funded partly by dilution (shares +9.7%), so the 'stronger' balance sheet came at shareholders' expense.